Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease
Identifieur interne : 000478 ( PascalFrancis/Corpus ); précédent : 000477; suivant : 000479Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease
Auteurs : Harvey D. White ; Claes Held ; Ralph Stewart ; Elizabeth Tarka ; Rebekkah Brown ; Richard Y. Davies ; Andrzej Budaj ; Robert A. Harrington ; P. Gabriel Steg ; Diego Ardissino ; Paul W. Armstrong ; Alvaro Avezum ; Philip E. Aylward ; Alfonso Bryce ; HONG CHEN ; Ming-Fong Chen ; Ramon Corbalan ; Anthony J. Dalby ; Nicolas Danchin ; Robbert J. De Winter ; Stefan Denchev ; Rafael Diaz ; Moses Elisaf ; Marcus D. Flather ; Assen R. Goudev ; Christopher B. Granger ; Liliana Grinfeld ; Judith S. Hochman ; Steen Husted ; Hyo-Soo Kim ; WOLFGANG KOENIG ; Ales Linhart ; Eva Lonn ; José Lopez-Sendon ; Athanasios J. Manolis ; Emile R. Iii Mohler ; José C. Nicolau ; Prem Pais ; Alexander Parkhomenko ; Terje R. Pedersen ; Daniel Pella ; Marco A. Ramos-Corrales ; Mikhail Ruda ; Mátyás Sereg ; Saulat Siddique ; Peter Sinnaeve ; Peter Smith ; Piyamitr Sritara ; Henk P. Swart ; Rody G. Sy ; Tamio Teramoto ; Hung-Fat Tse ; David Watson ; W. Douglas Weaver ; Robert Weiss ; Margus Viigimaa ; Dragos Vinereanu ; JUNREN ZHU ; Christopher P. CannonSource :
- The New England journal of medicine [ 0028-4793 ] ; 2014.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
BACKGROUND Elevated lipoprotein-associated phospholipase A2 activity promotes the development of vulnerable atherosclerotic plaques, and elevated plasma levels of this enzyme are associated with an increased risk of coronary events. Darapladib is a selective oral inhibitor of lipoprotein-associated phospholipase A2. METHODS In a double-blind trial, we randomly assigned 15,828 patients with stable coronary heart disease to receive either once-daily darapladib (at a dose of 160 mg) or placebo. The primary end point was the time to cardiovascular death, myocardial infarction, or stroke. Secondary end points included the components of the primary end point as well as major coronary events (death from coronary heart disease, myocardial infarction, or urgent coronary revascularization for myocardial ischemia) and total coronary events (death from coronary heart disease, myocardial infarction, hospitalization for unstable angina, or any coronary revascularization). RESULTS During a median follow-up period of 3.7 years, the primary end point occurred in 769 of 7924 patients (9.7%) in the darapladib group and 819 of 7904 patients (10.4%) in the placebo group (hazard ratio in the darapladib group, 0.94; 95% confidence interval [CI], 0.85 to 1.03; P=0.20).
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
| pA |
|
|---|
Format Inist (serveur)
| NO : | PASCAL 14-0105569 INIST |
|---|---|
| ET : | Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease |
| AU : | WHITE (Harvey D.); HELD (Claes); STEWART (Ralph); TARKA (Elizabeth); BROWN (Rebekkah); DAVIES (Richard Y.); BUDAJ (Andrzej); HARRINGTON (Robert A.); STEG (P. Gabriel); ARDISSINO (Diego); ARMSTRONG (Paul W.); AVEZUM (Alvaro); AYLWARD (Philip E.); BRYCE (Alfonso); HONG CHEN; CHEN (Ming-Fong); CORBALAN (Ramon); DALBY (Anthony J.); DANCHIN (Nicolas); DE WINTER (Robbert J.); DENCHEV (Stefan); DIAZ (Rafael); ELISAF (Moses); FLATHER (Marcus D.); GOUDEV (Assen R.); GRANGER (Christopher B.); GRINFELD (Liliana); HOCHMAN (Judith S.); HUSTED (Steen); KIM (Hyo-Soo); WOLFGANG KOENIG; LINHART (Ales); LONN (Eva); LOPEZ-SENDON (José); MANOLIS (Athanasios J.); MOHLER (Emile R. III); NICOLAU (José C.); PAIS (Prem); PARKHOMENKO (Alexander); PEDERSEN (Terje R.); PELLA (Daniel); RAMOS-CORRALES (Marco A.); RUDA (Mikhail); SEREG (Mátyás); SIDDIQUE (Saulat); SINNAEVE (Peter); SMITH (Peter); SRITARA (Piyamitr); SWART (Henk P.); SY (Rody G.); TERAMOTO (Tamio); TSE (Hung-Fat); WATSON (David); WEAVER (W. Douglas); WEISS (Robert); VIIGIMAA (Margus); VINEREANU (Dragos); JUNREN ZHU; CANNON (Christopher P.) |
| AF : | Green Lane Cardiovascular Service, Auckland City Hospital and University of Auckland/Auckland/Nouvelle-Zélande (1 aut., 3 aut.); Department of Medical Sciences, Cardiology, Uppsala University, and Uppsala Clinical Research Center/Uppsala/Suède (2 aut.); Metabolic Pathways and Cardiovascular Therapeutic Area, GlaxoSmithKline, King of Prussia/PA/Etats-Unis (4 aut., 6 aut.); Metabolic Pathways and Cardiovascular Therapeutic Area, GlaxoSmithKlineResearch Triangle Park/North Carolina/Etats-Unis (5 aut., 47 aut., 53 aut.); Duke University Medical Center/Durham, North Carolina/Etats-Unis (26 aut.); Postgraduate Medical School, Grochowski Hospital/Warsaw/Pologne (7 aut.); Department of Medicine, Stanford University/Stanford, CA/Etats-Unis (8 aut.); INSERM Unité 1148, Assistance Publique-Hôpitaux de Paris, Département Hospitalo-Universitaire FIRE, Hôpital Bichat/Paris/France (9 aut.); Université Paris-Diderot, Sorbonne-Paris Cité/Paris/France (9 aut.); Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, INSERM Unité 970 and Université Paris Descartes/Paris/France (19 aut.); NHLI Imperial College, ICMS, Royal Brompton Hospital/London/Royaume-Uni (9 aut.); Azienda Ospedaliero-Universitaria di Parma/Parma/Italie (10 aut.); Canadian VIGOUR Centre, University of Alberta/Edmonton/Canada (11 aut.); Department of Medicine and Population Health Research Institute, McMaster University/Hamilton, ON/Canada (33 aut.); Dante Pazzanese Institute of Cardiology/São Paulo/Brésil (12 aut.); Heart Institute (InCor), University of São Paulo Medical School/São Paulo/Brésil (37 aut.); South Australian Health and Medical Research Institute, Flinders University and Medical Centre/Adelaide, SA/Australie (13 aut.); Cardiogolf/Clinica El Golf/Lima/Pérou (14 aut.); Department of Cardiology, Peking University People's Hospital/Beijing/Chine (15 aut.); Department of Internal Medicine, National Taiwan University Hospital/Taipei/Taïwan (16 aut.); Cardiovascular Division Pontificia Universidad Catolica de Chile/Santiago/Chili (17 aut.); Milpark Hospital/Johannesburg/Afrique du Sud (18 aut.); Department of Cardiology, Academic Medical Center, University of Amsterdam/Amsterdam/Pays-Bas (20 aut.); Clinic of Cardiology, University Hospital Alexandrovska/Sofia/Bulgarie (21 aut.); Cardiology Department, Queen Giovanna University Hospital/Sofia/Bulgarie (25 aut.) |
| DT : | Publication en série; Niveau analytique |
| SO : | The New England journal of medicine; ISSN 0028-4793; Coden NEJMAG; Etats-Unis; Da. 2014; Vol. 370; No. 18; Pp. 1702-1711; Bibl. 22 ref. |
| LA : | Anglais |
| EA : | BACKGROUND Elevated lipoprotein-associated phospholipase A2 activity promotes the development of vulnerable atherosclerotic plaques, and elevated plasma levels of this enzyme are associated with an increased risk of coronary events. Darapladib is a selective oral inhibitor of lipoprotein-associated phospholipase A2. METHODS In a double-blind trial, we randomly assigned 15,828 patients with stable coronary heart disease to receive either once-daily darapladib (at a dose of 160 mg) or placebo. The primary end point was the time to cardiovascular death, myocardial infarction, or stroke. Secondary end points included the components of the primary end point as well as major coronary events (death from coronary heart disease, myocardial infarction, or urgent coronary revascularization for myocardial ischemia) and total coronary events (death from coronary heart disease, myocardial infarction, hospitalization for unstable angina, or any coronary revascularization). RESULTS During a median follow-up period of 3.7 years, the primary end point occurred in 769 of 7924 patients (9.7%) in the darapladib group and 819 of 7904 patients (10.4%) in the placebo group (hazard ratio in the darapladib group, 0.94; 95% confidence interval [CI], 0.85 to 1.03; P=0.20). |
| CC : | 002B01; 002B12A03 |
| FD : | Ischémie; Cardiopathie coronaire; Darapladib; Prévention; Médecine |
| FG : | Pathologie de l'appareil circulatoire; Inhibiteur de la phospholipase A2 |
| ED : | Ischemia; Coronary heart disease; Darapladib; Prevention; Medicine |
| EG : | Cardiovascular disease |
| SD : | Isquemia; Cardiopatía coronaria; Darapladib; Prevención; Medicina |
| LO : | INIST-6013.354000500437940060 |
| ID : | 14-0105569 |
Links to Exploration step
Pascal:14-0105569Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease</title><author><name sortKey="White, Harvey D" sort="White, Harvey D" uniqKey="White H" first="Harvey D." last="White">Harvey D. White</name><affiliation><inist:fA14 i1="01"><s1>Green Lane Cardiovascular Service, Auckland City Hospital and University of Auckland</s1><s2>Auckland</s2><s3>NZL</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Held, Claes" sort="Held, Claes" uniqKey="Held C" first="Claes" last="Held">Claes Held</name><affiliation><inist:fA14 i1="02"><s1>Department of Medical Sciences, Cardiology, Uppsala University, and Uppsala Clinical Research Center</s1><s2>Uppsala</s2><s3>SWE</s3><sZ>2 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Stewart, Ralph" sort="Stewart, Ralph" uniqKey="Stewart R" first="Ralph" last="Stewart">Ralph Stewart</name><affiliation><inist:fA14 i1="01"><s1>Green Lane Cardiovascular Service, Auckland City Hospital and University of Auckland</s1><s2>Auckland</s2><s3>NZL</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Tarka, Elizabeth" sort="Tarka, Elizabeth" uniqKey="Tarka E" first="Elizabeth" last="Tarka">Elizabeth Tarka</name><affiliation><inist:fA14 i1="03"><s1>Metabolic Pathways and Cardiovascular Therapeutic Area, GlaxoSmithKline, King of Prussia</s1><s2>PA</s2><s3>USA</s3><sZ>4 aut.</sZ><sZ>6 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Brown, Rebekkah" sort="Brown, Rebekkah" uniqKey="Brown R" first="Rebekkah" last="Brown">Rebekkah Brown</name><affiliation><inist:fA14 i1="04"><s1>Metabolic Pathways and Cardiovascular Therapeutic Area, GlaxoSmithKlineResearch Triangle Park</s1><s2>North Carolina</s2><s3>USA</s3><sZ>5 aut.</sZ><sZ>47 aut.</sZ><sZ>53 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Davies, Richard Y" sort="Davies, Richard Y" uniqKey="Davies R" first="Richard Y." last="Davies">Richard Y. Davies</name><affiliation><inist:fA14 i1="03"><s1>Metabolic Pathways and Cardiovascular Therapeutic Area, GlaxoSmithKline, King of Prussia</s1><s2>PA</s2><s3>USA</s3><sZ>4 aut.</sZ><sZ>6 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Budaj, Andrzej" sort="Budaj, Andrzej" uniqKey="Budaj A" first="Andrzej" last="Budaj">Andrzej Budaj</name><affiliation><inist:fA14 i1="06"><s1>Postgraduate Medical School, Grochowski Hospital</s1><s2>Warsaw</s2><s3>POL</s3><sZ>7 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Harrington, Robert A" sort="Harrington, Robert A" uniqKey="Harrington R" first="Robert A." last="Harrington">Robert A. Harrington</name><affiliation><inist:fA14 i1="07"><s1>Department of Medicine, Stanford University</s1><s2>Stanford, CA</s2><s3>USA</s3><sZ>8 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Steg, P Gabriel" sort="Steg, P Gabriel" uniqKey="Steg P" first="P. Gabriel" last="Steg">P. Gabriel Steg</name><affiliation><inist:fA14 i1="08"><s1>INSERM Unité 1148, Assistance Publique-Hôpitaux de Paris, Département Hospitalo-Universitaire FIRE, Hôpital Bichat</s1><s2>Paris</s2><s3>FRA</s3><sZ>9 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="09"><s1>Université Paris-Diderot, Sorbonne-Paris Cité</s1><s2>Paris</s2><s3>FRA</s3><sZ>9 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="11"><s1>NHLI Imperial College, ICMS, Royal Brompton Hospital</s1><s2>London</s2><s3>GBR</s3><sZ>9 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Ardissino, Diego" sort="Ardissino, Diego" uniqKey="Ardissino D" first="Diego" last="Ardissino">Diego Ardissino</name><affiliation><inist:fA14 i1="12"><s1>Azienda Ospedaliero-Universitaria di Parma</s1><s2>Parma</s2><s3>ITA</s3><sZ>10 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Armstrong, Paul W" sort="Armstrong, Paul W" uniqKey="Armstrong P" first="Paul W." last="Armstrong">Paul W. Armstrong</name><affiliation><inist:fA14 i1="13"><s1>Canadian VIGOUR Centre, University of Alberta</s1><s2>Edmonton</s2><s3>CAN</s3><sZ>11 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Avezum, Alvaro" sort="Avezum, Alvaro" uniqKey="Avezum A" first="Alvaro" last="Avezum">Alvaro Avezum</name><affiliation><inist:fA14 i1="15"><s1>Dante Pazzanese Institute of Cardiology</s1><s2>São Paulo</s2><s3>BRA</s3><sZ>12 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Aylward, Philip E" sort="Aylward, Philip E" uniqKey="Aylward P" first="Philip E." last="Aylward">Philip E. Aylward</name><affiliation><inist:fA14 i1="17"><s1>South Australian Health and Medical Research Institute, Flinders University and Medical Centre</s1><s2>Adelaide, SA</s2><s3>AUS</s3><sZ>13 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Bryce, Alfonso" sort="Bryce, Alfonso" uniqKey="Bryce A" first="Alfonso" last="Bryce">Alfonso Bryce</name><affiliation><inist:fA14 i1="18"><s1>Cardiogolf/Clinica El Golf</s1><s2>Lima</s2><s3>PER</s3><sZ>14 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Hong Chen" sort="Hong Chen" uniqKey="Hong Chen" last="Hong Chen">HONG CHEN</name><affiliation><inist:fA14 i1="19"><s1>Department of Cardiology, Peking University People's Hospital</s1><s2>Beijing</s2><s3>CHN</s3><sZ>15 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Chen, Ming Fong" sort="Chen, Ming Fong" uniqKey="Chen M" first="Ming-Fong" last="Chen">Ming-Fong Chen</name><affiliation><inist:fA14 i1="20"><s1>Department of Internal Medicine, National Taiwan University Hospital</s1><s2>Taipei</s2><s3>TWN</s3><sZ>16 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Corbalan, Ramon" sort="Corbalan, Ramon" uniqKey="Corbalan R" first="Ramon" last="Corbalan">Ramon Corbalan</name><affiliation><inist:fA14 i1="21"><s1>Cardiovascular Division Pontificia Universidad Catolica de Chile</s1><s2>Santiago</s2><s3>CHL</s3><sZ>17 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Dalby, Anthony J" sort="Dalby, Anthony J" uniqKey="Dalby A" first="Anthony J." last="Dalby">Anthony J. Dalby</name><affiliation><inist:fA14 i1="22"><s1>Milpark Hospital</s1><s2>Johannesburg</s2><s3>ZAF</s3><sZ>18 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Danchin, Nicolas" sort="Danchin, Nicolas" uniqKey="Danchin N" first="Nicolas" last="Danchin">Nicolas Danchin</name><affiliation><inist:fA14 i1="10"><s1>Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, INSERM Unité 970 and Université Paris Descartes</s1><s2>Paris</s2><s3>FRA</s3><sZ>19 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="De Winter, Robbert J" sort="De Winter, Robbert J" uniqKey="De Winter R" first="Robbert J." last="De Winter">Robbert J. De Winter</name><affiliation><inist:fA14 i1="23"><s1>Department of Cardiology, Academic Medical Center, University of Amsterdam</s1><s2>Amsterdam</s2><s3>NLD</s3><sZ>20 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Denchev, Stefan" sort="Denchev, Stefan" uniqKey="Denchev S" first="Stefan" last="Denchev">Stefan Denchev</name><affiliation><inist:fA14 i1="24"><s1>Clinic of Cardiology, University Hospital Alexandrovska</s1><s2>Sofia</s2><s3>BGR</s3><sZ>21 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Diaz, Rafael" sort="Diaz, Rafael" uniqKey="Diaz R" first="Rafael" last="Diaz">Rafael Diaz</name></author><author><name sortKey="Elisaf, Moses" sort="Elisaf, Moses" uniqKey="Elisaf M" first="Moses" last="Elisaf">Moses Elisaf</name></author><author><name sortKey="Flather, Marcus D" sort="Flather, Marcus D" uniqKey="Flather M" first="Marcus D." last="Flather">Marcus D. Flather</name></author><author><name sortKey="Goudev, Assen R" sort="Goudev, Assen R" uniqKey="Goudev A" first="Assen R." last="Goudev">Assen R. Goudev</name><affiliation><inist:fA14 i1="25"><s1>Cardiology Department, Queen Giovanna University Hospital</s1><s2>Sofia</s2><s3>BGR</s3><sZ>25 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Granger, Christopher B" sort="Granger, Christopher B" uniqKey="Granger C" first="Christopher B." last="Granger">Christopher B. Granger</name><affiliation><inist:fA14 i1="05"><s1>Duke University Medical Center</s1><s2>Durham, North Carolina</s2><s3>USA</s3><sZ>26 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Grinfeld, Liliana" sort="Grinfeld, Liliana" uniqKey="Grinfeld L" first="Liliana" last="Grinfeld">Liliana Grinfeld</name></author><author><name sortKey="Hochman, Judith S" sort="Hochman, Judith S" uniqKey="Hochman J" first="Judith S." last="Hochman">Judith S. Hochman</name></author><author><name sortKey="Husted, Steen" sort="Husted, Steen" uniqKey="Husted S" first="Steen" last="Husted">Steen Husted</name></author><author><name sortKey="Kim, Hyo Soo" sort="Kim, Hyo Soo" uniqKey="Kim H" first="Hyo-Soo" last="Kim">Hyo-Soo Kim</name></author><author><name sortKey="Wolfgang Koenig" sort="Wolfgang Koenig" uniqKey="Wolfgang Koenig" last="Wolfgang Koenig">WOLFGANG KOENIG</name></author><author><name sortKey="Linhart, Ales" sort="Linhart, Ales" uniqKey="Linhart A" first="Ales" last="Linhart">Ales Linhart</name></author><author><name sortKey="Lonn, Eva" sort="Lonn, Eva" uniqKey="Lonn E" first="Eva" last="Lonn">Eva Lonn</name><affiliation><inist:fA14 i1="14"><s1>Department of Medicine and Population Health Research Institute, McMaster University</s1><s2>Hamilton, ON</s2><s3>CAN</s3><sZ>33 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Lopez Sendon, Jose" sort="Lopez Sendon, Jose" uniqKey="Lopez Sendon J" first="José" last="Lopez-Sendon">José Lopez-Sendon</name></author><author><name sortKey="Manolis, Athanasios J" sort="Manolis, Athanasios J" uniqKey="Manolis A" first="Athanasios J." last="Manolis">Athanasios J. Manolis</name></author><author><name sortKey="Mohler, Emile R Iii" sort="Mohler, Emile R Iii" uniqKey="Mohler E" first="Emile R. Iii" last="Mohler">Emile R. Iii Mohler</name></author><author><name sortKey="Nicolau, Jose C" sort="Nicolau, Jose C" uniqKey="Nicolau J" first="José C." last="Nicolau">José C. Nicolau</name><affiliation><inist:fA14 i1="16"><s1>Heart Institute (InCor), University of São Paulo Medical School</s1><s2>São Paulo</s2><s3>BRA</s3><sZ>37 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Pais, Prem" sort="Pais, Prem" uniqKey="Pais P" first="Prem" last="Pais">Prem Pais</name></author><author><name sortKey="Parkhomenko, Alexander" sort="Parkhomenko, Alexander" uniqKey="Parkhomenko A" first="Alexander" last="Parkhomenko">Alexander Parkhomenko</name></author><author><name sortKey="Pedersen, Terje R" sort="Pedersen, Terje R" uniqKey="Pedersen T" first="Terje R." last="Pedersen">Terje R. Pedersen</name></author><author><name sortKey="Pella, Daniel" sort="Pella, Daniel" uniqKey="Pella D" first="Daniel" last="Pella">Daniel Pella</name></author><author><name sortKey="Ramos Corrales, Marco A" sort="Ramos Corrales, Marco A" uniqKey="Ramos Corrales M" first="Marco A." last="Ramos-Corrales">Marco A. Ramos-Corrales</name></author><author><name sortKey="Ruda, Mikhail" sort="Ruda, Mikhail" uniqKey="Ruda M" first="Mikhail" last="Ruda">Mikhail Ruda</name></author><author><name sortKey="Sereg, Matyas" sort="Sereg, Matyas" uniqKey="Sereg M" first="Mátyás" last="Sereg">Mátyás Sereg</name></author><author><name sortKey="Siddique, Saulat" sort="Siddique, Saulat" uniqKey="Siddique S" first="Saulat" last="Siddique">Saulat Siddique</name></author><author><name sortKey="Sinnaeve, Peter" sort="Sinnaeve, Peter" uniqKey="Sinnaeve P" first="Peter" last="Sinnaeve">Peter Sinnaeve</name></author><author><name sortKey="Smith, Peter" sort="Smith, Peter" uniqKey="Smith P" first="Peter" last="Smith">Peter Smith</name><affiliation><inist:fA14 i1="04"><s1>Metabolic Pathways and Cardiovascular Therapeutic Area, GlaxoSmithKlineResearch Triangle Park</s1><s2>North Carolina</s2><s3>USA</s3><sZ>5 aut.</sZ><sZ>47 aut.</sZ><sZ>53 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Sritara, Piyamitr" sort="Sritara, Piyamitr" uniqKey="Sritara P" first="Piyamitr" last="Sritara">Piyamitr Sritara</name></author><author><name sortKey="Swart, Henk P" sort="Swart, Henk P" uniqKey="Swart H" first="Henk P." last="Swart">Henk P. Swart</name></author><author><name sortKey="Sy, Rody G" sort="Sy, Rody G" uniqKey="Sy R" first="Rody G." last="Sy">Rody G. Sy</name></author><author><name sortKey="Teramoto, Tamio" sort="Teramoto, Tamio" uniqKey="Teramoto T" first="Tamio" last="Teramoto">Tamio Teramoto</name></author><author><name sortKey="Tse, Hung Fat" sort="Tse, Hung Fat" uniqKey="Tse H" first="Hung-Fat" last="Tse">Hung-Fat Tse</name></author><author><name sortKey="Watson, David" sort="Watson, David" uniqKey="Watson D" first="David" last="Watson">David Watson</name><affiliation><inist:fA14 i1="04"><s1>Metabolic Pathways and Cardiovascular Therapeutic Area, GlaxoSmithKlineResearch Triangle Park</s1><s2>North Carolina</s2><s3>USA</s3><sZ>5 aut.</sZ><sZ>47 aut.</sZ><sZ>53 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Weaver, W Douglas" sort="Weaver, W Douglas" uniqKey="Weaver W" first="W. Douglas" last="Weaver">W. Douglas Weaver</name></author><author><name sortKey="Weiss, Robert" sort="Weiss, Robert" uniqKey="Weiss R" first="Robert" last="Weiss">Robert Weiss</name></author><author><name sortKey="Viigimaa, Margus" sort="Viigimaa, Margus" uniqKey="Viigimaa M" first="Margus" last="Viigimaa">Margus Viigimaa</name></author><author><name sortKey="Vinereanu, Dragos" sort="Vinereanu, Dragos" uniqKey="Vinereanu D" first="Dragos" last="Vinereanu">Dragos Vinereanu</name></author><author><name sortKey="Junren Zhu" sort="Junren Zhu" uniqKey="Junren Zhu" last="Junren Zhu">JUNREN ZHU</name></author><author><name sortKey="Cannon, Christopher P" sort="Cannon, Christopher P" uniqKey="Cannon C" first="Christopher P." last="Cannon">Christopher P. Cannon</name></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">14-0105569</idno><date when="2014">2014</date><idno type="stanalyst">PASCAL 14-0105569 INIST</idno><idno type="RBID">Pascal:14-0105569</idno><idno type="wicri:Area/PascalFrancis/Corpus">000478</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease</title><author><name sortKey="White, Harvey D" sort="White, Harvey D" uniqKey="White H" first="Harvey D." last="White">Harvey D. White</name><affiliation><inist:fA14 i1="01"><s1>Green Lane Cardiovascular Service, Auckland City Hospital and University of Auckland</s1><s2>Auckland</s2><s3>NZL</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Held, Claes" sort="Held, Claes" uniqKey="Held C" first="Claes" last="Held">Claes Held</name><affiliation><inist:fA14 i1="02"><s1>Department of Medical Sciences, Cardiology, Uppsala University, and Uppsala Clinical Research Center</s1><s2>Uppsala</s2><s3>SWE</s3><sZ>2 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Stewart, Ralph" sort="Stewart, Ralph" uniqKey="Stewart R" first="Ralph" last="Stewart">Ralph Stewart</name><affiliation><inist:fA14 i1="01"><s1>Green Lane Cardiovascular Service, Auckland City Hospital and University of Auckland</s1><s2>Auckland</s2><s3>NZL</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Tarka, Elizabeth" sort="Tarka, Elizabeth" uniqKey="Tarka E" first="Elizabeth" last="Tarka">Elizabeth Tarka</name><affiliation><inist:fA14 i1="03"><s1>Metabolic Pathways and Cardiovascular Therapeutic Area, GlaxoSmithKline, King of Prussia</s1><s2>PA</s2><s3>USA</s3><sZ>4 aut.</sZ><sZ>6 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Brown, Rebekkah" sort="Brown, Rebekkah" uniqKey="Brown R" first="Rebekkah" last="Brown">Rebekkah Brown</name><affiliation><inist:fA14 i1="04"><s1>Metabolic Pathways and Cardiovascular Therapeutic Area, GlaxoSmithKlineResearch Triangle Park</s1><s2>North Carolina</s2><s3>USA</s3><sZ>5 aut.</sZ><sZ>47 aut.</sZ><sZ>53 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Davies, Richard Y" sort="Davies, Richard Y" uniqKey="Davies R" first="Richard Y." last="Davies">Richard Y. Davies</name><affiliation><inist:fA14 i1="03"><s1>Metabolic Pathways and Cardiovascular Therapeutic Area, GlaxoSmithKline, King of Prussia</s1><s2>PA</s2><s3>USA</s3><sZ>4 aut.</sZ><sZ>6 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Budaj, Andrzej" sort="Budaj, Andrzej" uniqKey="Budaj A" first="Andrzej" last="Budaj">Andrzej Budaj</name><affiliation><inist:fA14 i1="06"><s1>Postgraduate Medical School, Grochowski Hospital</s1><s2>Warsaw</s2><s3>POL</s3><sZ>7 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Harrington, Robert A" sort="Harrington, Robert A" uniqKey="Harrington R" first="Robert A." last="Harrington">Robert A. Harrington</name><affiliation><inist:fA14 i1="07"><s1>Department of Medicine, Stanford University</s1><s2>Stanford, CA</s2><s3>USA</s3><sZ>8 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Steg, P Gabriel" sort="Steg, P Gabriel" uniqKey="Steg P" first="P. Gabriel" last="Steg">P. Gabriel Steg</name><affiliation><inist:fA14 i1="08"><s1>INSERM Unité 1148, Assistance Publique-Hôpitaux de Paris, Département Hospitalo-Universitaire FIRE, Hôpital Bichat</s1><s2>Paris</s2><s3>FRA</s3><sZ>9 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="09"><s1>Université Paris-Diderot, Sorbonne-Paris Cité</s1><s2>Paris</s2><s3>FRA</s3><sZ>9 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="11"><s1>NHLI Imperial College, ICMS, Royal Brompton Hospital</s1><s2>London</s2><s3>GBR</s3><sZ>9 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Ardissino, Diego" sort="Ardissino, Diego" uniqKey="Ardissino D" first="Diego" last="Ardissino">Diego Ardissino</name><affiliation><inist:fA14 i1="12"><s1>Azienda Ospedaliero-Universitaria di Parma</s1><s2>Parma</s2><s3>ITA</s3><sZ>10 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Armstrong, Paul W" sort="Armstrong, Paul W" uniqKey="Armstrong P" first="Paul W." last="Armstrong">Paul W. Armstrong</name><affiliation><inist:fA14 i1="13"><s1>Canadian VIGOUR Centre, University of Alberta</s1><s2>Edmonton</s2><s3>CAN</s3><sZ>11 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Avezum, Alvaro" sort="Avezum, Alvaro" uniqKey="Avezum A" first="Alvaro" last="Avezum">Alvaro Avezum</name><affiliation><inist:fA14 i1="15"><s1>Dante Pazzanese Institute of Cardiology</s1><s2>São Paulo</s2><s3>BRA</s3><sZ>12 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Aylward, Philip E" sort="Aylward, Philip E" uniqKey="Aylward P" first="Philip E." last="Aylward">Philip E. Aylward</name><affiliation><inist:fA14 i1="17"><s1>South Australian Health and Medical Research Institute, Flinders University and Medical Centre</s1><s2>Adelaide, SA</s2><s3>AUS</s3><sZ>13 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Bryce, Alfonso" sort="Bryce, Alfonso" uniqKey="Bryce A" first="Alfonso" last="Bryce">Alfonso Bryce</name><affiliation><inist:fA14 i1="18"><s1>Cardiogolf/Clinica El Golf</s1><s2>Lima</s2><s3>PER</s3><sZ>14 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Hong Chen" sort="Hong Chen" uniqKey="Hong Chen" last="Hong Chen">HONG CHEN</name><affiliation><inist:fA14 i1="19"><s1>Department of Cardiology, Peking University People's Hospital</s1><s2>Beijing</s2><s3>CHN</s3><sZ>15 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Chen, Ming Fong" sort="Chen, Ming Fong" uniqKey="Chen M" first="Ming-Fong" last="Chen">Ming-Fong Chen</name><affiliation><inist:fA14 i1="20"><s1>Department of Internal Medicine, National Taiwan University Hospital</s1><s2>Taipei</s2><s3>TWN</s3><sZ>16 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Corbalan, Ramon" sort="Corbalan, Ramon" uniqKey="Corbalan R" first="Ramon" last="Corbalan">Ramon Corbalan</name><affiliation><inist:fA14 i1="21"><s1>Cardiovascular Division Pontificia Universidad Catolica de Chile</s1><s2>Santiago</s2><s3>CHL</s3><sZ>17 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Dalby, Anthony J" sort="Dalby, Anthony J" uniqKey="Dalby A" first="Anthony J." last="Dalby">Anthony J. Dalby</name><affiliation><inist:fA14 i1="22"><s1>Milpark Hospital</s1><s2>Johannesburg</s2><s3>ZAF</s3><sZ>18 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Danchin, Nicolas" sort="Danchin, Nicolas" uniqKey="Danchin N" first="Nicolas" last="Danchin">Nicolas Danchin</name><affiliation><inist:fA14 i1="10"><s1>Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, INSERM Unité 970 and Université Paris Descartes</s1><s2>Paris</s2><s3>FRA</s3><sZ>19 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="De Winter, Robbert J" sort="De Winter, Robbert J" uniqKey="De Winter R" first="Robbert J." last="De Winter">Robbert J. De Winter</name><affiliation><inist:fA14 i1="23"><s1>Department of Cardiology, Academic Medical Center, University of Amsterdam</s1><s2>Amsterdam</s2><s3>NLD</s3><sZ>20 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Denchev, Stefan" sort="Denchev, Stefan" uniqKey="Denchev S" first="Stefan" last="Denchev">Stefan Denchev</name><affiliation><inist:fA14 i1="24"><s1>Clinic of Cardiology, University Hospital Alexandrovska</s1><s2>Sofia</s2><s3>BGR</s3><sZ>21 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Diaz, Rafael" sort="Diaz, Rafael" uniqKey="Diaz R" first="Rafael" last="Diaz">Rafael Diaz</name></author><author><name sortKey="Elisaf, Moses" sort="Elisaf, Moses" uniqKey="Elisaf M" first="Moses" last="Elisaf">Moses Elisaf</name></author><author><name sortKey="Flather, Marcus D" sort="Flather, Marcus D" uniqKey="Flather M" first="Marcus D." last="Flather">Marcus D. Flather</name></author><author><name sortKey="Goudev, Assen R" sort="Goudev, Assen R" uniqKey="Goudev A" first="Assen R." last="Goudev">Assen R. Goudev</name><affiliation><inist:fA14 i1="25"><s1>Cardiology Department, Queen Giovanna University Hospital</s1><s2>Sofia</s2><s3>BGR</s3><sZ>25 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Granger, Christopher B" sort="Granger, Christopher B" uniqKey="Granger C" first="Christopher B." last="Granger">Christopher B. Granger</name><affiliation><inist:fA14 i1="05"><s1>Duke University Medical Center</s1><s2>Durham, North Carolina</s2><s3>USA</s3><sZ>26 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Grinfeld, Liliana" sort="Grinfeld, Liliana" uniqKey="Grinfeld L" first="Liliana" last="Grinfeld">Liliana Grinfeld</name></author><author><name sortKey="Hochman, Judith S" sort="Hochman, Judith S" uniqKey="Hochman J" first="Judith S." last="Hochman">Judith S. Hochman</name></author><author><name sortKey="Husted, Steen" sort="Husted, Steen" uniqKey="Husted S" first="Steen" last="Husted">Steen Husted</name></author><author><name sortKey="Kim, Hyo Soo" sort="Kim, Hyo Soo" uniqKey="Kim H" first="Hyo-Soo" last="Kim">Hyo-Soo Kim</name></author><author><name sortKey="Wolfgang Koenig" sort="Wolfgang Koenig" uniqKey="Wolfgang Koenig" last="Wolfgang Koenig">WOLFGANG KOENIG</name></author><author><name sortKey="Linhart, Ales" sort="Linhart, Ales" uniqKey="Linhart A" first="Ales" last="Linhart">Ales Linhart</name></author><author><name sortKey="Lonn, Eva" sort="Lonn, Eva" uniqKey="Lonn E" first="Eva" last="Lonn">Eva Lonn</name><affiliation><inist:fA14 i1="14"><s1>Department of Medicine and Population Health Research Institute, McMaster University</s1><s2>Hamilton, ON</s2><s3>CAN</s3><sZ>33 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Lopez Sendon, Jose" sort="Lopez Sendon, Jose" uniqKey="Lopez Sendon J" first="José" last="Lopez-Sendon">José Lopez-Sendon</name></author><author><name sortKey="Manolis, Athanasios J" sort="Manolis, Athanasios J" uniqKey="Manolis A" first="Athanasios J." last="Manolis">Athanasios J. Manolis</name></author><author><name sortKey="Mohler, Emile R Iii" sort="Mohler, Emile R Iii" uniqKey="Mohler E" first="Emile R. Iii" last="Mohler">Emile R. Iii Mohler</name></author><author><name sortKey="Nicolau, Jose C" sort="Nicolau, Jose C" uniqKey="Nicolau J" first="José C." last="Nicolau">José C. Nicolau</name><affiliation><inist:fA14 i1="16"><s1>Heart Institute (InCor), University of São Paulo Medical School</s1><s2>São Paulo</s2><s3>BRA</s3><sZ>37 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Pais, Prem" sort="Pais, Prem" uniqKey="Pais P" first="Prem" last="Pais">Prem Pais</name></author><author><name sortKey="Parkhomenko, Alexander" sort="Parkhomenko, Alexander" uniqKey="Parkhomenko A" first="Alexander" last="Parkhomenko">Alexander Parkhomenko</name></author><author><name sortKey="Pedersen, Terje R" sort="Pedersen, Terje R" uniqKey="Pedersen T" first="Terje R." last="Pedersen">Terje R. Pedersen</name></author><author><name sortKey="Pella, Daniel" sort="Pella, Daniel" uniqKey="Pella D" first="Daniel" last="Pella">Daniel Pella</name></author><author><name sortKey="Ramos Corrales, Marco A" sort="Ramos Corrales, Marco A" uniqKey="Ramos Corrales M" first="Marco A." last="Ramos-Corrales">Marco A. Ramos-Corrales</name></author><author><name sortKey="Ruda, Mikhail" sort="Ruda, Mikhail" uniqKey="Ruda M" first="Mikhail" last="Ruda">Mikhail Ruda</name></author><author><name sortKey="Sereg, Matyas" sort="Sereg, Matyas" uniqKey="Sereg M" first="Mátyás" last="Sereg">Mátyás Sereg</name></author><author><name sortKey="Siddique, Saulat" sort="Siddique, Saulat" uniqKey="Siddique S" first="Saulat" last="Siddique">Saulat Siddique</name></author><author><name sortKey="Sinnaeve, Peter" sort="Sinnaeve, Peter" uniqKey="Sinnaeve P" first="Peter" last="Sinnaeve">Peter Sinnaeve</name></author><author><name sortKey="Smith, Peter" sort="Smith, Peter" uniqKey="Smith P" first="Peter" last="Smith">Peter Smith</name><affiliation><inist:fA14 i1="04"><s1>Metabolic Pathways and Cardiovascular Therapeutic Area, GlaxoSmithKlineResearch Triangle Park</s1><s2>North Carolina</s2><s3>USA</s3><sZ>5 aut.</sZ><sZ>47 aut.</sZ><sZ>53 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Sritara, Piyamitr" sort="Sritara, Piyamitr" uniqKey="Sritara P" first="Piyamitr" last="Sritara">Piyamitr Sritara</name></author><author><name sortKey="Swart, Henk P" sort="Swart, Henk P" uniqKey="Swart H" first="Henk P." last="Swart">Henk P. Swart</name></author><author><name sortKey="Sy, Rody G" sort="Sy, Rody G" uniqKey="Sy R" first="Rody G." last="Sy">Rody G. Sy</name></author><author><name sortKey="Teramoto, Tamio" sort="Teramoto, Tamio" uniqKey="Teramoto T" first="Tamio" last="Teramoto">Tamio Teramoto</name></author><author><name sortKey="Tse, Hung Fat" sort="Tse, Hung Fat" uniqKey="Tse H" first="Hung-Fat" last="Tse">Hung-Fat Tse</name></author><author><name sortKey="Watson, David" sort="Watson, David" uniqKey="Watson D" first="David" last="Watson">David Watson</name><affiliation><inist:fA14 i1="04"><s1>Metabolic Pathways and Cardiovascular Therapeutic Area, GlaxoSmithKlineResearch Triangle Park</s1><s2>North Carolina</s2><s3>USA</s3><sZ>5 aut.</sZ><sZ>47 aut.</sZ><sZ>53 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Weaver, W Douglas" sort="Weaver, W Douglas" uniqKey="Weaver W" first="W. Douglas" last="Weaver">W. Douglas Weaver</name></author><author><name sortKey="Weiss, Robert" sort="Weiss, Robert" uniqKey="Weiss R" first="Robert" last="Weiss">Robert Weiss</name></author><author><name sortKey="Viigimaa, Margus" sort="Viigimaa, Margus" uniqKey="Viigimaa M" first="Margus" last="Viigimaa">Margus Viigimaa</name></author><author><name sortKey="Vinereanu, Dragos" sort="Vinereanu, Dragos" uniqKey="Vinereanu D" first="Dragos" last="Vinereanu">Dragos Vinereanu</name></author><author><name sortKey="Junren Zhu" sort="Junren Zhu" uniqKey="Junren Zhu" last="Junren Zhu">JUNREN ZHU</name></author><author><name sortKey="Cannon, Christopher P" sort="Cannon, Christopher P" uniqKey="Cannon C" first="Christopher P." last="Cannon">Christopher P. Cannon</name></author></analytic><series><title level="j" type="main">The New England journal of medicine</title><title level="j" type="abbreviated">N. Engl. j. med.</title><idno type="ISSN">0028-4793</idno><imprint><date when="2014">2014</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">The New England journal of medicine</title><title level="j" type="abbreviated">N. Engl. j. med.</title><idno type="ISSN">0028-4793</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Coronary heart disease</term><term>Darapladib</term><term>Ischemia</term><term>Medicine</term><term>Prevention</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Ischémie</term><term>Cardiopathie coronaire</term><term>Darapladib</term><term>Prévention</term><term>Médecine</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">BACKGROUND Elevated lipoprotein-associated phospholipase A<sub>2</sub> activity promotes the development of vulnerable atherosclerotic plaques, and elevated plasma levels of this enzyme are associated with an increased risk of coronary events. Darapladib is a selective oral inhibitor of lipoprotein-associated phospholipase A<sub>2</sub>. METHODS In a double-blind trial, we randomly assigned 15,828 patients with stable coronary heart disease to receive either once-daily darapladib (at a dose of 160 mg) or placebo. The primary end point was the time to cardiovascular death, myocardial infarction, or stroke. Secondary end points included the components of the primary end point as well as major coronary events (death from coronary heart disease, myocardial infarction, or urgent coronary revascularization for myocardial ischemia) and total coronary events (death from coronary heart disease, myocardial infarction, hospitalization for unstable angina, or any coronary revascularization). RESULTS During a median follow-up period of 3.7 years, the primary end point occurred in 769 of 7924 patients (9.7%) in the darapladib group and 819 of 7904 patients (10.4%) in the placebo group (hazard ratio in the darapladib group, 0.94; 95% confidence interval [CI], 0.85 to 1.03; P=0.20).</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0028-4793</s0></fA01><fA02 i1="01"><s0>NEJMAG</s0></fA02><fA03 i2="1"><s0>N. Engl. j. med.</s0></fA03><fA05><s2>370</s2></fA05><fA06><s2>18</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease</s1></fA08><fA11 i1="01" i2="1"><s1>WHITE (Harvey D.)</s1></fA11><fA11 i1="02" i2="1"><s1>HELD (Claes)</s1></fA11><fA11 i1="03" i2="1"><s1>STEWART (Ralph)</s1></fA11><fA11 i1="04" i2="1"><s1>TARKA (Elizabeth)</s1></fA11><fA11 i1="05" i2="1"><s1>BROWN (Rebekkah)</s1></fA11><fA11 i1="06" i2="1"><s1>DAVIES (Richard Y.)</s1></fA11><fA11 i1="07" i2="1"><s1>BUDAJ (Andrzej)</s1></fA11><fA11 i1="08" i2="1"><s1>HARRINGTON (Robert A.)</s1></fA11><fA11 i1="09" i2="1"><s1>STEG (P. Gabriel)</s1></fA11><fA11 i1="10" i2="1"><s1>ARDISSINO (Diego)</s1></fA11><fA11 i1="11" i2="1"><s1>ARMSTRONG (Paul W.)</s1></fA11><fA11 i1="12" i2="1"><s1>AVEZUM (Alvaro)</s1></fA11><fA11 i1="13" i2="1"><s1>AYLWARD (Philip E.)</s1></fA11><fA11 i1="14" i2="1"><s1>BRYCE (Alfonso)</s1></fA11><fA11 i1="15" i2="1"><s1>HONG CHEN</s1></fA11><fA11 i1="16" i2="1"><s1>CHEN (Ming-Fong)</s1></fA11><fA11 i1="17" i2="1"><s1>CORBALAN (Ramon)</s1></fA11><fA11 i1="18" i2="1"><s1>DALBY (Anthony J.)</s1></fA11><fA11 i1="19" i2="1"><s1>DANCHIN (Nicolas)</s1></fA11><fA11 i1="20" i2="1"><s1>DE WINTER (Robbert J.)</s1></fA11><fA11 i1="21" i2="1"><s1>DENCHEV (Stefan)</s1></fA11><fA11 i1="22" i2="1"><s1>DIAZ (Rafael)</s1></fA11><fA11 i1="23" i2="1"><s1>ELISAF (Moses)</s1></fA11><fA11 i1="24" i2="1"><s1>FLATHER (Marcus D.)</s1></fA11><fA11 i1="25" i2="1"><s1>GOUDEV (Assen R.)</s1></fA11><fA11 i1="26" i2="1"><s1>GRANGER (Christopher B.)</s1></fA11><fA11 i1="27" i2="1"><s1>GRINFELD (Liliana)</s1></fA11><fA11 i1="28" i2="1"><s1>HOCHMAN (Judith S.)</s1></fA11><fA11 i1="29" i2="1"><s1>HUSTED (Steen)</s1></fA11><fA11 i1="30" i2="1"><s1>KIM (Hyo-Soo)</s1></fA11><fA11 i1="31" i2="1"><s1>WOLFGANG KOENIG</s1></fA11><fA11 i1="32" i2="1"><s1>LINHART (Ales)</s1></fA11><fA11 i1="33" i2="1"><s1>LONN (Eva)</s1></fA11><fA11 i1="34" i2="1"><s1>LOPEZ-SENDON (José)</s1></fA11><fA11 i1="35" i2="1"><s1>MANOLIS (Athanasios J.)</s1></fA11><fA11 i1="36" i2="1"><s1>MOHLER (Emile R. III)</s1></fA11><fA11 i1="37" i2="1"><s1>NICOLAU (José C.)</s1></fA11><fA11 i1="38" i2="1"><s1>PAIS (Prem)</s1></fA11><fA11 i1="39" i2="1"><s1>PARKHOMENKO (Alexander)</s1></fA11><fA11 i1="40" i2="1"><s1>PEDERSEN (Terje R.)</s1></fA11><fA11 i1="41" i2="1"><s1>PELLA (Daniel)</s1></fA11><fA11 i1="42" i2="1"><s1>RAMOS-CORRALES (Marco A.)</s1></fA11><fA11 i1="43" i2="1"><s1>RUDA (Mikhail)</s1></fA11><fA11 i1="44" i2="1"><s1>SEREG (Mátyás)</s1></fA11><fA11 i1="45" i2="1"><s1>SIDDIQUE (Saulat)</s1></fA11><fA11 i1="46" i2="1"><s1>SINNAEVE (Peter)</s1></fA11><fA11 i1="47" i2="1"><s1>SMITH (Peter)</s1></fA11><fA11 i1="48" i2="1"><s1>SRITARA (Piyamitr)</s1></fA11><fA11 i1="49" i2="1"><s1>SWART (Henk P.)</s1></fA11><fA11 i1="50" i2="1"><s1>SY (Rody G.)</s1></fA11><fA11 i1="51" i2="1"><s1>TERAMOTO (Tamio)</s1></fA11><fA11 i1="52" i2="1"><s1>TSE (Hung-Fat)</s1></fA11><fA11 i1="53" i2="1"><s1>WATSON (David)</s1></fA11><fA11 i1="54" i2="1"><s1>WEAVER (W. Douglas)</s1></fA11><fA11 i1="55" i2="1"><s1>WEISS (Robert)</s1></fA11><fA11 i1="56" i2="1"><s1>VIIGIMAA (Margus)</s1></fA11><fA11 i1="57" i2="1"><s1>VINEREANU (Dragos)</s1></fA11><fA11 i1="58" i2="1"><s1>JUNREN ZHU</s1></fA11><fA11 i1="59" i2="1"><s1>CANNON (Christopher P.)</s1></fA11><fA14 i1="01"><s1>Green Lane Cardiovascular Service, Auckland City Hospital and University of Auckland</s1><s2>Auckland</s2><s3>NZL</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ></fA14><fA14 i1="02"><s1>Department of Medical Sciences, Cardiology, Uppsala University, and Uppsala Clinical Research Center</s1><s2>Uppsala</s2><s3>SWE</s3><sZ>2 aut.</sZ></fA14><fA14 i1="03"><s1>Metabolic Pathways and Cardiovascular Therapeutic Area, GlaxoSmithKline, King of Prussia</s1><s2>PA</s2><s3>USA</s3><sZ>4 aut.</sZ><sZ>6 aut.</sZ></fA14><fA14 i1="04"><s1>Metabolic Pathways and Cardiovascular Therapeutic Area, GlaxoSmithKlineResearch Triangle Park</s1><s2>North Carolina</s2><s3>USA</s3><sZ>5 aut.</sZ><sZ>47 aut.</sZ><sZ>53 aut.</sZ></fA14><fA14 i1="05"><s1>Duke University Medical Center</s1><s2>Durham, North Carolina</s2><s3>USA</s3><sZ>26 aut.</sZ></fA14><fA14 i1="06"><s1>Postgraduate Medical School, Grochowski Hospital</s1><s2>Warsaw</s2><s3>POL</s3><sZ>7 aut.</sZ></fA14><fA14 i1="07"><s1>Department of Medicine, Stanford University</s1><s2>Stanford, CA</s2><s3>USA</s3><sZ>8 aut.</sZ></fA14><fA14 i1="08"><s1>INSERM Unité 1148, Assistance Publique-Hôpitaux de Paris, Département Hospitalo-Universitaire FIRE, Hôpital Bichat</s1><s2>Paris</s2><s3>FRA</s3><sZ>9 aut.</sZ></fA14><fA14 i1="09"><s1>Université Paris-Diderot, Sorbonne-Paris Cité</s1><s2>Paris</s2><s3>FRA</s3><sZ>9 aut.</sZ></fA14><fA14 i1="10"><s1>Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, INSERM Unité 970 and Université Paris Descartes</s1><s2>Paris</s2><s3>FRA</s3><sZ>19 aut.</sZ></fA14><fA14 i1="11"><s1>NHLI Imperial College, ICMS, Royal Brompton Hospital</s1><s2>London</s2><s3>GBR</s3><sZ>9 aut.</sZ></fA14><fA14 i1="12"><s1>Azienda Ospedaliero-Universitaria di Parma</s1><s2>Parma</s2><s3>ITA</s3><sZ>10 aut.</sZ></fA14><fA14 i1="13"><s1>Canadian VIGOUR Centre, University of Alberta</s1><s2>Edmonton</s2><s3>CAN</s3><sZ>11 aut.</sZ></fA14><fA14 i1="14"><s1>Department of Medicine and Population Health Research Institute, McMaster University</s1><s2>Hamilton, ON</s2><s3>CAN</s3><sZ>33 aut.</sZ></fA14><fA14 i1="15"><s1>Dante Pazzanese Institute of Cardiology</s1><s2>São Paulo</s2><s3>BRA</s3><sZ>12 aut.</sZ></fA14><fA14 i1="16"><s1>Heart Institute (InCor), University of São Paulo Medical School</s1><s2>São Paulo</s2><s3>BRA</s3><sZ>37 aut.</sZ></fA14><fA14 i1="17"><s1>South Australian Health and Medical Research Institute, Flinders University and Medical Centre</s1><s2>Adelaide, SA</s2><s3>AUS</s3><sZ>13 aut.</sZ></fA14><fA14 i1="18"><s1>Cardiogolf/Clinica El Golf</s1><s2>Lima</s2><s3>PER</s3><sZ>14 aut.</sZ></fA14><fA14 i1="19"><s1>Department of Cardiology, Peking University People's Hospital</s1><s2>Beijing</s2><s3>CHN</s3><sZ>15 aut.</sZ></fA14><fA14 i1="20"><s1>Department of Internal Medicine, National Taiwan University Hospital</s1><s2>Taipei</s2><s3>TWN</s3><sZ>16 aut.</sZ></fA14><fA14 i1="21"><s1>Cardiovascular Division Pontificia Universidad Catolica de Chile</s1><s2>Santiago</s2><s3>CHL</s3><sZ>17 aut.</sZ></fA14><fA14 i1="22"><s1>Milpark Hospital</s1><s2>Johannesburg</s2><s3>ZAF</s3><sZ>18 aut.</sZ></fA14><fA14 i1="23"><s1>Department of Cardiology, Academic Medical Center, University of Amsterdam</s1><s2>Amsterdam</s2><s3>NLD</s3><sZ>20 aut.</sZ></fA14><fA14 i1="24"><s1>Clinic of Cardiology, University Hospital Alexandrovska</s1><s2>Sofia</s2><s3>BGR</s3><sZ>21 aut.</sZ></fA14><fA14 i1="25"><s1>Cardiology Department, Queen Giovanna University Hospital</s1><s2>Sofia</s2><s3>BGR</s3><sZ>25 aut.</sZ></fA14><fA17 i1="01" i2="1"><s1>STABILITY Investigators</s1><s3>INC</s3></fA17><fA20><s1>1702-1711</s1></fA20><fA21><s1>2014</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>6013</s2><s5>354000500437940060</s5></fA43><fA44><s0>0000</s0><s1>© 2014 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>22 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>14-0105569</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>The New England journal of medicine</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>BACKGROUND Elevated lipoprotein-associated phospholipase A<sub>2</sub> activity promotes the development of vulnerable atherosclerotic plaques, and elevated plasma levels of this enzyme are associated with an increased risk of coronary events. Darapladib is a selective oral inhibitor of lipoprotein-associated phospholipase A<sub>2</sub>. METHODS In a double-blind trial, we randomly assigned 15,828 patients with stable coronary heart disease to receive either once-daily darapladib (at a dose of 160 mg) or placebo. The primary end point was the time to cardiovascular death, myocardial infarction, or stroke. Secondary end points included the components of the primary end point as well as major coronary events (death from coronary heart disease, myocardial infarction, or urgent coronary revascularization for myocardial ischemia) and total coronary events (death from coronary heart disease, myocardial infarction, hospitalization for unstable angina, or any coronary revascularization). RESULTS During a median follow-up period of 3.7 years, the primary end point occurred in 769 of 7924 patients (9.7%) in the darapladib group and 819 of 7904 patients (10.4%) in the placebo group (hazard ratio in the darapladib group, 0.94; 95% confidence interval [CI], 0.85 to 1.03; P=0.20).</s0></fC01><fC02 i1="01" i2="X"><s0>002B01</s0></fC02><fC02 i1="02" i2="X"><s0>002B12A03</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Ischémie</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Ischemia</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Isquemia</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Cardiopathie coronaire</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Coronary heart disease</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Cardiopatía coronaria</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Darapladib</s0><s2>FR</s2><s5>04</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Darapladib</s0><s2>FR</s2><s5>04</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Darapladib</s0><s2>FR</s2><s5>04</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Prévention</s0><s5>07</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Prevention</s0><s5>07</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Prevención</s0><s5>07</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Médecine</s0><s5>08</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Medicine</s0><s5>08</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Medicina</s0><s5>08</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'appareil circulatoire</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Cardiovascular disease</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Aparato circulatorio patología</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Inhibiteur de la phospholipase A2</s0><s4>INC</s4><s5>86</s5></fC07><fN21><s1>139</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard><server><NO>PASCAL 14-0105569 INIST</NO><ET>Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease</ET><AU>WHITE (Harvey D.); HELD (Claes); STEWART (Ralph); TARKA (Elizabeth); BROWN (Rebekkah); DAVIES (Richard Y.); BUDAJ (Andrzej); HARRINGTON (Robert A.); STEG (P. Gabriel); ARDISSINO (Diego); ARMSTRONG (Paul W.); AVEZUM (Alvaro); AYLWARD (Philip E.); BRYCE (Alfonso); HONG CHEN; CHEN (Ming-Fong); CORBALAN (Ramon); DALBY (Anthony J.); DANCHIN (Nicolas); DE WINTER (Robbert J.); DENCHEV (Stefan); DIAZ (Rafael); ELISAF (Moses); FLATHER (Marcus D.); GOUDEV (Assen R.); GRANGER (Christopher B.); GRINFELD (Liliana); HOCHMAN (Judith S.); HUSTED (Steen); KIM (Hyo-Soo); WOLFGANG KOENIG; LINHART (Ales); LONN (Eva); LOPEZ-SENDON (José); MANOLIS (Athanasios J.); MOHLER (Emile R. III); NICOLAU (José C.); PAIS (Prem); PARKHOMENKO (Alexander); PEDERSEN (Terje R.); PELLA (Daniel); RAMOS-CORRALES (Marco A.); RUDA (Mikhail); SEREG (Mátyás); SIDDIQUE (Saulat); SINNAEVE (Peter); SMITH (Peter); SRITARA (Piyamitr); SWART (Henk P.); SY (Rody G.); TERAMOTO (Tamio); TSE (Hung-Fat); WATSON (David); WEAVER (W. Douglas); WEISS (Robert); VIIGIMAA (Margus); VINEREANU (Dragos); JUNREN ZHU; CANNON (Christopher P.)</AU><AF>Green Lane Cardiovascular Service, Auckland City Hospital and University of Auckland/Auckland/Nouvelle-Zélande (1 aut., 3 aut.); Department of Medical Sciences, Cardiology, Uppsala University, and Uppsala Clinical Research Center/Uppsala/Suède (2 aut.); Metabolic Pathways and Cardiovascular Therapeutic Area, GlaxoSmithKline, King of Prussia/PA/Etats-Unis (4 aut., 6 aut.); Metabolic Pathways and Cardiovascular Therapeutic Area, GlaxoSmithKlineResearch Triangle Park/North Carolina/Etats-Unis (5 aut., 47 aut., 53 aut.); Duke University Medical Center/Durham, North Carolina/Etats-Unis (26 aut.); Postgraduate Medical School, Grochowski Hospital/Warsaw/Pologne (7 aut.); Department of Medicine, Stanford University/Stanford, CA/Etats-Unis (8 aut.); INSERM Unité 1148, Assistance Publique-Hôpitaux de Paris, Département Hospitalo-Universitaire FIRE, Hôpital Bichat/Paris/France (9 aut.); Université Paris-Diderot, Sorbonne-Paris Cité/Paris/France (9 aut.); Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, INSERM Unité 970 and Université Paris Descartes/Paris/France (19 aut.); NHLI Imperial College, ICMS, Royal Brompton Hospital/London/Royaume-Uni (9 aut.); Azienda Ospedaliero-Universitaria di Parma/Parma/Italie (10 aut.); Canadian VIGOUR Centre, University of Alberta/Edmonton/Canada (11 aut.); Department of Medicine and Population Health Research Institute, McMaster University/Hamilton, ON/Canada (33 aut.); Dante Pazzanese Institute of Cardiology/São Paulo/Brésil (12 aut.); Heart Institute (InCor), University of São Paulo Medical School/São Paulo/Brésil (37 aut.); South Australian Health and Medical Research Institute, Flinders University and Medical Centre/Adelaide, SA/Australie (13 aut.); Cardiogolf/Clinica El Golf/Lima/Pérou (14 aut.); Department of Cardiology, Peking University People's Hospital/Beijing/Chine (15 aut.); Department of Internal Medicine, National Taiwan University Hospital/Taipei/Taïwan (16 aut.); Cardiovascular Division Pontificia Universidad Catolica de Chile/Santiago/Chili (17 aut.); Milpark Hospital/Johannesburg/Afrique du Sud (18 aut.); Department of Cardiology, Academic Medical Center, University of Amsterdam/Amsterdam/Pays-Bas (20 aut.); Clinic of Cardiology, University Hospital Alexandrovska/Sofia/Bulgarie (21 aut.); Cardiology Department, Queen Giovanna University Hospital/Sofia/Bulgarie (25 aut.)</AF><DT>Publication en série; Niveau analytique</DT><SO>The New England journal of medicine; ISSN 0028-4793; Coden NEJMAG; Etats-Unis; Da. 2014; Vol. 370; No. 18; Pp. 1702-1711; Bibl. 22 ref.</SO><LA>Anglais</LA><EA>BACKGROUND Elevated lipoprotein-associated phospholipase A<sub>2</sub> activity promotes the development of vulnerable atherosclerotic plaques, and elevated plasma levels of this enzyme are associated with an increased risk of coronary events. Darapladib is a selective oral inhibitor of lipoprotein-associated phospholipase A<sub>2</sub>. METHODS In a double-blind trial, we randomly assigned 15,828 patients with stable coronary heart disease to receive either once-daily darapladib (at a dose of 160 mg) or placebo. The primary end point was the time to cardiovascular death, myocardial infarction, or stroke. Secondary end points included the components of the primary end point as well as major coronary events (death from coronary heart disease, myocardial infarction, or urgent coronary revascularization for myocardial ischemia) and total coronary events (death from coronary heart disease, myocardial infarction, hospitalization for unstable angina, or any coronary revascularization). RESULTS During a median follow-up period of 3.7 years, the primary end point occurred in 769 of 7924 patients (9.7%) in the darapladib group and 819 of 7904 patients (10.4%) in the placebo group (hazard ratio in the darapladib group, 0.94; 95% confidence interval [CI], 0.85 to 1.03; P=0.20).</EA><CC>002B01; 002B12A03</CC><FD>Ischémie; Cardiopathie coronaire; Darapladib; Prévention; Médecine</FD><FG>Pathologie de l'appareil circulatoire; Inhibiteur de la phospholipase A2</FG><ED>Ischemia; Coronary heart disease; Darapladib; Prevention; Medicine</ED><EG>Cardiovascular disease</EG><SD>Isquemia; Cardiopatía coronaria; Darapladib; Prevención; Medicina</SD><LO>INIST-6013.354000500437940060</LO><ID>14-0105569</ID></server></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000478 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000478 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PascalFrancis
|étape= Corpus
|type= RBID
|clé= Pascal:14-0105569
|texte= Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease
}}
| This area was generated with Dilib version V0.6.33. |  |